Insulin Legislation Progresses with Bipartisan Support

Bipartisan legislation aimed at capping the price of insulin at $35 per month for individuals with private insurance is gaining traction in Congress. Initially introduced in March, the bill recently gained additional support with four new co-sponsors: Senators Joni Ernst (R-Iowa), John Hickenlooper (D-Colo.), Kevin Cramer (R-N.D.), and Angela Alsobrooks (D-Md.). Currently, the bill boasts 22 bipartisan co-sponsors. This development arises amidst efforts by Congress to address healthcare affordability concerns. An April KFF poll highlighted the high cost of healthcare as a top concern for Americans.

This legislative proposal was previously introduced in 2023 with 13 co-sponsors, including seven Republicans, but it failed to progress beyond committee hearings. The current version of the bill is championed by Democratic Senators Jeanne Shaheen (N.H.), Raphael Warnock (Ga.), and Republicans Susan Collins (Maine) and John Kennedy (La.). It intends to extend the existing $35 insulin cap for Medicare recipients, enacted under the Inflation Reduction Act, to cover plans available on the ObamaCare marketplaces as well as other commercial plans.

Additionally, the proposal includes a pilot grant program for 10 states to offer uninsured diabetes patients insulin at $35 per month. The bill mandates that group and individual market health plans waive any deductibles and limit monthly cost-sharing to a maximum of $35 or 25% of the insulin’s list price for at least one product of each type and dosage form.

Lawmakers likely aim to link this legislation to essential bills that must pass by the year’s end, including several healthcare program extensions.

Welcome to The Hill’s Health Care newsletter. Stay informed about the latest developments in Washington that impact health policy. From changes in medical education’s nutrition requirements announced by the Department of Health and Human Services (HHS) to the approaching ban on hemp-derived intoxicants, we cover diverse health care topics.

President Trump recently announced an expansion of his administration’s direct-to-consumer drug platform, TrumpRx, by adding over 100 prescription medications. This expansion brings the total to more than 800 common prescription drugs available at reduced prices.

On Our Radar

Upcoming events and themes to watch include the House Appropriations Committee’s review of the FY 2027 HHS funding bill. In related news, fast food chain Steak ‘n Shake celebrated the victory of a candidate it endorsed for Iowa governor, showcasing its political prediction success.

Around the Nation

• Debates continue over the risks of high-potency cannabis in some states.
• Texas has seen a 123% increase in its healthcare workforce over 30 years, but state officials indicate it is still insufficient.
• In North Carolina, the State Health Plan board agreed to raise costs for certain retirees starting in 2027.